Impact of Limb Amputation and Cisplatin Chemotherapy on Metastatic Progression in Mouse Models of Osteosarcoma
Authors
Affiliations
Development of animal models that accurately recapitulate human cancer is an ongoing challenge. This is particularly relevant in the study of osteosarcoma (OS), a highly malignant bone tumor diagnosed in approximately 1000 pediatric/adolescent patients each year. Metastasis is the leading cause of patient death underscoring the need for relevant animal models of metastatic OS. In this study, we describe how existing OS mouse models can be interrogated in a time-course context to determine the kinetics of spontaneous metastasis from an orthotopically implanted primary tumor. We evaluated four highly metastatic OS cell lines (3 human, 1 mouse) to establish a timeline for metastatic progression in immune deficient NSG mice. To discern the effects of therapy on tumor development and metastasis in these models, we investigated cisplatin therapy and surgical limb amputation at early and late timepoints. These data help define the appropriate observational periods for studies of metastatic progression in OS and further our understanding of existing mouse models. Efforts to advance the study of metastatic OS are critical for facilitating the identification of novel therapeutics and for improving patient survival.
Peng P, Wang H, Pang Z, Zhang H, Hu S, Ma X Mol Cell Biochem. 2025; .
PMID: 40050510 DOI: 10.1007/s11010-025-05246-7.
Pharmacologic Inhibition of EIF4A Blocks NRF2 Synthesis to Prevent Osteosarcoma Metastasis.
Lizardo M, Hughes C, Huang Y, Shyp T, Delaidelli A, Zhang H Clin Cancer Res. 2024; 30(19):4464-4481.
PMID: 39078310 PMC: 11443218. DOI: 10.1158/1078-0432.CCR-24-1317.
OBSERVE: guidelines for the refinement of rodent cancer models.
De Vleeschauwer S, van de Ven M, Oudin A, Debusschere K, Connor K, Byrne A Nat Protoc. 2024; 19(9):2571-2596.
PMID: 38992214 DOI: 10.1038/s41596-024-00998-w.
Dhobale K, Sahoo L Plant Cell Rep. 2024; 43(7):173.
PMID: 38877163 DOI: 10.1007/s00299-024-03247-2.
MLASM: Machine learning based prediction of anticancer small molecules.
Balaji P, Selvam S, Sohn H, Madhavan T Mol Divers. 2024; 28(4):2153-2161.
PMID: 38554168 DOI: 10.1007/s11030-024-10823-x.